BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/25/2025 9:42:13 AM | Browse: 0 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li-Juan Nie, Gao-Xiang Wang, Xin-Yi Yang, Jing Sun, Yu-Tian Cao, Yan Lou, Yi-Fan Lu, Jiang-Yi Yu and Xi-Qiao Zhou |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82474318 |
| Jiangsu Administration of Traditional Chinese Medicine |
No. QN202411 |
| Special Fund for Training Outstanding Young Doctors in the Second Session of Jiangsu Province Hospital of Chinese Medicine |
No. 2024QB002 |
|
| Corresponding Author |
Xi-Qiao Zhou, Director, PhD, Professor, Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No. 155 Hanzhong Road, Qinhuai District, Nanjing 210029, Jiangsu Province, China. zhouxiqiao@njucm.edu.cn |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Traditional Chinese medicine; Peroxisome proliferator-activated receptor alpha; Inflammation; Network pharmacology |
| Core Tip |
Lianhe Xiaozhi ointment effectively alleviates metabolic dysfunction-associated steatotic liver disease by improving glucolipid metabolism, reducing liver injury and inflammation, and modulating gut microbiota. Its therapeutic effect is primarily mediated via activation of peroxisome proliferator-activated receptor alpha signaling. These insights provide a theoretical foundation for the clinical application of Lianhe Xiaozhi ointment. |
| Citation |
Nie LJ, Wang GX, Yang XY, Sun J, Cao YT, Lou Y, Lu YF, Yu JY, Zhou XQ. Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. World J Gastroenterol 2025; In press |
 |
Received |
|
2025-09-30 03:07 |
 |
Peer-Review Started |
|
2025-09-30 03:07 |
 |
First Decision by Editorial Office Director |
|
2025-10-27 09:52 |
 |
Return for Revision |
|
2025-10-27 09:52 |
 |
Revised |
|
2025-11-06 04:02 |
 |
Publication Fee Transferred |
|
2025-11-10 09:05 |
 |
Second Decision by Editor |
|
2025-12-25 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-25 09:42 |
 |
Articles in Press |
|
2025-12-25 09:42 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345